The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia
Rattachement africain : hr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Non–small cell lung cancer (NSCLC) has become the best example of precision oncology’s impact on outcomes in everyday clinical practice, significantly changing the expectations of all stakeholders, including medical professionals, society, and most importantly, patients. Consequently, the implementation of the precision oncology concept in medical systems, in order to achieve optimal and proven curative effects in NSCLC, is imperative. In this study, we investigated the development, challenges, and results associated with the implementation of precision oncology in NSCLC on a national level in Croatia. We conducted a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients with metastatic lung cancer, on whose tumors specimen comprehensive genomic profiling (CGP) testing was performed during 2020 and 2021. A total of 48 patients were included in the study. CGP revealed clinically relevant genomic alterations (CRGA) in 37 patients (79%), with a median of 2 (IQR 1–3) CRGA per patient. From the panel of recommended tests, KRAS, MET, and EGFR were the most common alterations, detected in 16 (34%), 5 (11%), and 3 (6%) patients, respectively. CGP revealed additional targetable mutations in 29 (60%) patients who would not have been tested (and consequently, whose mutations would not have been detected) according to the existing everyday standard of practice in Croatia. The tumor mutational burden was reported as high (≥10 Muts/Mb) in 19 patients (40%). CGP analysis reported some kind of targeted therapy for 34 patients (72%). CGP revealed other potentially targetable mutations, and it also determined TMB to be high in a significant number of patients. In conclusion, when possible, CGP should be used as an upfront backbone diagnostic and treatment-oriented work-up in patients with NSCLC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia
- Date Crossref
- 28/06/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Split pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Centre Zagreb pays non établi dans la noticeÉtablissement de santé
-
University of Zagreb pays non établi dans la noticeUniversité ou école supérieure
-
University of Rijeka pays non établi dans la noticeUniversité ou école supérieure
-
University of Osijek pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Center Split Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Center Zagreb Department for Respiratory Diseases Jordanovac pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital for Tumors Department of Oncology and Nuclear Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Center Osijek Department of Radiotherapy Oncology pays non établi dans la noticeUniversité ou école supérieure
University of Split, University Hospital Centre Zagreb et University of Zagreb, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.